[1] Mohan C, Putterman C. Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis[J]. Nat Rev Nephrol, 2015,11(6):329-341.
[2] Almaani S, Meara A, Rovin B H. Update on Lupus Nephritis[J]. Clin J Am Soc Nephrol, 2017,12(5):825-835.
[3] Gao H, Li C, Mu R, et al. Subclinical hypothyroidism and its association with lupus nephritis: a case control study in a large cohort of Chinese systemic lupus erythematosus patients[J]. Lupus, 2011,20(10):1035-1041.
[4] Luo W, Mao P, Zhang L, et al. Association between systemic lupus erythematosus and thyroid dysfunction: a meta-analysis[J]. Lupus, 2018,27(13):2120-2128.
[5] Liu Y C, Lin W Y, Tsai M C, et al. Systemic lupus erythematosus and thyroid disease - Experience in a single medical center in Taiwan[J]. J Microbiol Immunol Infect, 2019,52(3):480-486.
[6] Watad A, Mahroum N, Whitby A, et al. Hypothyroidism among SLE patients: Case-control study[J]. Autoimmun Rev, 2016,15(5):484-486.
[7] Al S J, El S M, Jassim V, et al. Hypothyroidism determines the clinical and immunological manifestations of Arabs with lupus[J]. Lupus, 2008,17(3):215-220.
[8] Mader R, Mishail S, Adawi M, et al. Thyroid dysfunction in patients with systemic lupus erythematosus (SLE): relation to disease activity[J]. Clin Rheumatol, 2007,26(11):1891-1894.
[9] Watad A, Mahroum N, Whitby A, et al. Hypothyroidism among SLE patients: Case-control study[J]. Autoimmun Rev, 2016,15(5):484-486.
[10] Sainani K L. Logistic regression[J]. PM R, 2014,6(12):1157-1162.
[11] Jolliffe I T, Cadima J. Principal component analysis: a review and recent developments[J]. Philos Trans A Math Phys Eng Sci, 2016,374(2065):20150202.
[12] Ringner M. What is principal component analysis?[J]. Nat Biotechnol, 2008,26(3):303-304.
[13] Raymond W D, Eilertsen G Ø, Nossent J. Principal component analysis reveals disconnect between regulatory cytokines and disease activity in Systemic Lupus Erythematosus[J]. Cytokine, 2019,114:67-73.
[14] Helmy A, Antoniades C A, Guilfoyle M R, et al. Principal component analysis of the cytokine and chemokine response to human traumatic brain injury[J]. PloS one, 2012,7(6):e39677.
[15] Iglesias P, Bajo M A, Selgas R, et al. Thyroid dysfunction and kidney disease: An update[J]. Rev Endocr Metab Disord, 2017,18(1):131-144.
[16] Montenegro J, Gonzalez O, Saracho R, et al. Changes in renal function in primary hypothyroidism[J]. Am J Kidney Dis, 1996,27(2):195-198.
[17] Villabona C, Sahun M, Roca M, et al. Blood volumes and renal function in overt and subclinical primary hypothyroidism[J]. Am J Med Sci, 1999,318(4):277-280.
[18] Zimmerman R S, Ryan J, Edwards B S, et al. Cardiorenal endocrine dynamics during volume expansion in hypothyroid dogs[J]. Am J Physiol, 1988,255(1 Pt 2):R61-R66.
[19] Schmid C, Brandle M, Zwimpfer C, et al. Effect of thyroxine replacement on creatinine, insulin-like growth factor 1, acid-labile subunit, and vascular endothelial growth factor[J]. Clin Chem, 2004,50(1):228-231.
[20] Mondal S, Raja K, Schweizer U, et al. Chemistry and Biology in the Biosynthesis and Action of Thyroid Hormones[J]. Angew Chem Int Ed Engl, 2016,55(27):7606-7630.
[21] Braun D, Schweizer U. Thyroid Hormone Transport and Transporters[J]. Vitam Horm, 2018,106:19-44.
[22] Joasoo A, Murray I P, Parkin J, et al. Abnormalities of in vitro thyroid function tests in renal disease[J]. Q J Med, 1974,43(170):245-261.
[23] Lim V S, Fang V S, Katz A I, et al. Thyroid dysfunction in chronic renal failure. A study of the pituitary-thyroid axis and peripheral turnover kinetics of thyroxine and triiodothyronine[J]. J Clin Invest, 1977,60(3):522-534.
[24] Migliorini P, Baldini C, Rocchi V, et al. Anti-Sm and anti-RNP antibodies[J]. Autoimmunity, 2009,38(1):47-54.
[25] Sharp G C, Irvin W S, May C M, et al. Association of antibodies to ribonucleoprotein and Sm antigens with mixed connective-tissue disease, systematic lupus erythematosus and other rheumatic diseases[J]. N Engl J Med, 1976,295(21):1149-1154.
[26] Bastian H M, Roseman J M, McGwin G J, et al. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis[J]. Lupus, 2002,11(3):152-160.
[27] Greidinger E L, Zang Y, Fernandez I, et al. Tissue targeting of anti-RNP autoimmunity: Effects of T cells and myeloid dendritic cells in a murine model[J]. Arthritis & Rheumatism, 2009,60(2):534-542.
[28] Arbuckle M R, McClain M T, Rubertone M V, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus[J]. N Engl J Med, 2003,349(16):1526-1533.
[29] Greidinger E L, Hoffman R W. The appearance of U1 RNP antibody specificities in sequential autoimmune human antisera follows a characteristic order that implicates the U1-70 kd and B'/B proteins as predominant U1 RNP immunogens[J]. Arthritis Rheum, 2001,44(2):368-375.
[30] Siriwardhane T, Krishna K, Ranganathan V, et al. Exploring Systemic Autoimmunity in Thyroid Disease Subjects[J]. Journal of Immunology Research, 2018,2018:1-7.